摘要
目的探讨促甲状腺激素(thyroid stimulating hormone,TSH)抑制疗法对老年甲状腺癌患者血清可溶性白细胞介素-2受体(soluble interleukin-2 receptor,s IL-2R)、白细胞分化抗原44变异型6(CD44V6)、肿瘤特异性生长因子(tumors pecific growth factor,TSGF)及外周血T淋巴细胞亚群(peripheral blood T lymphocyte subsets,PBTLS)影响。方法收集的本院收治的老年甲状腺癌患者50例,随机分为对照组和实验组,每组各25例,实验组术后给予TSH抑制疗法,对照组术后给予甲状腺素替代疗法,治疗1个月后,对所有患者的血清sIL-2R、CD44V6、TSGF及外周血T淋巴细胞亚群情况进行检测。结果治疗后,与对照组比较,1实验组患者血清sIL-2R水平较低,差异具有统计学意义(P<0.05);2实验组患者的血清CD44V6水平较低(P<0.05);3实验组患者的血清TSGF水平较低(P<0.05);4实验组患者外周血CD3+、CD4+水平较高,CD8+水平较低(P<0.05)。结论 TSH抑制疗法能够降低老年甲状腺癌患者血清s IL-2R、CD44V6、TSGF及淋巴细胞CD8+水平,使外周血T淋巴细胞CD3+、CD4+水平升高,改善患者免疫功能,对临床有指导意义。
Objective To analyze the effect of TSH inhibition on soluble interleukin 2 receptor ( sIL-2R), interleukin 44 variant 6 (CD44V6), tumor specific growth factor (TSGF) and T lymphocyte subsets in elderly patients with thyroid cancer.Methods 50 elderly patients with thyroid cancer in our hospital were collected.The patients were randomly assigned to experimental and control groups, 25 cases in each group, patients in the experimental group were given TSH suppression therapy after surgery , patients in control group were given thyroxine replacement therapy after operation, treatment for 1 month, serum SIL-2R, CD44v6, TSGF and peripheral blood T lymphocyte subsets situation were detected in all patients with .ResuIts After treatment, compared with the control group, ①in the experimental group, the level of serum sIL-2R was significantly lower, the difference was statistically significant(P<0.05);②the serum CD44V6 level was lower in the experimental group (P<0.05);③the serum TSGF level was lower in the experimental group (P<0.05);③in the experimental group,the levels of CD3 + and CD4 +were higher, levels of CD8 + were lower ( P<0.05 ) .ConcIusions TSH suppression therapy can reduce senile thyroid cancer patients serum SIL-2R, CD44v6, TSGF and CD8 +lymphocyte level, peripheral blood T lymphocyte CD3 +, CD4 +levels were elevated,and improve the immune function of patients , the clinical has guiding significance .
出处
《中国生化药物杂志》
CAS
2015年第7期104-106,共3页
Chinese Journal of Biochemical Pharmaceutics
